Results 101 to 110 of about 73,649 (308)

Combination strategy exploration for prior treated recurrent or metastatic nasopharyngeal carcinoma in the era of immunotherapy

Scientific Reports
To assess the efficacy and safety of the combination of immune checkpoint inhibitors (ICIs) and target therapy (anti-angiogenesis or EGFR inhibitors) as a second-line or subsequent treatment for recurrent or metastatic nasopharyngeal carcinoma (R/M NPC),
Yaofei Jiang, Chun Chen, Guoying Liu, Ting Fang, Nian Lu, Weixin Bei, Shuhui Dong, Wangzhong Li, Weixiong Xia, Hu Liang, Yanqun Xiang   +10 more
doaj   +1 more source

Diet and nasopharyngeal carcinoma [PDF]

FEMS Microbiology Letters, 1990
Nasopharyngeal carcinoma (NPC) is a disease with a remarkable racial and geographical distribution. It is very rare (incidence of less than 1 per 100,000 person-years) in most parts of the world and only a handful of populations are known to deviate from this low-risk profile, which include people of southern China.
openaire   +3 more sources

Emerging treatment options for nasopharyngeal carcinoma

, 2013
Lu Zhang,1,2 Qiu-Yan Chen,1,2 Huai Liu,1,2 Lin-Quan Tang,1,2 Hai-Qiang Mai1,21State Key Laboratory of Oncology in South China, 2Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou, People's Republic of ...
Liu H, Chen QY, Tang LQ, Mai HQ, Zhang L
core  

Disease Site‐Specific Outcomes in p16‐Positive Non‐Oropharyngeal Mucosal Head and Neck Cancer

Head &Neck, EarlyView.
ABSTRACT Objectives To report disease‐free survival (DFS) in p16‐positive non‐oropharyngeal head‐and‐neck squamous‐cell carcinoma (HNSCC). Methods Curatively‐treated non‐oropharyngeal HNSCC (2009–2021) were reviewed. DFS was compared among p16‐positive, p16‐negative, and p16‐untested cases for the overall cohort and by disease site.
Revadhi C. Chelvarajah, Lessandra Y. S. Chee, Jie Su, Brian O'Sullivan, Christopher M. K. L. Yao, Enrique Sanz‐Garcia, Stephen M. Smith, Ilan Weinreb, Scott Bratman, B. C. John Cho, Ezra Hahn, Andrew Hope, Ali Hosni, John Kim, Andrew McPartlin, Nauman Malik, Chiaojung Jillian Tsai, John de Almeida, Anna Spreafico, Li Tong, Shao Hui Huang, John N Waldron   +21 more
wiley   +1 more source

Nasopharyngeal Carcinoma [PDF]

Head and Neck Pathology, 2012
Laura N, Carle, Charles C, Ko, James T, Castle   +2 more
openaire   +2 more sources

CCL26‐Mediated Modulation of Endothelial Secretome by Hypoxia‐Induced Tumor‐Derived Exosomes Enhances Metastatic Progression in Head and Neck Cancer

Head &Neck, EarlyView.
ABSTRACT Background Tumor cells adapt to hypoxia by releasing hiTDExs enriched with bioactive molecules that modulate endothelial behavior and promote tumor progression. This study aimed to characterize how hypoxia‐induced HNSCC exosomes reshape the endothelial secretome and contribute to metastatic potential.
Ozel Capik, Sevil Tekman, Betul Gundogdu, Ahsen Kilic, Rumeysa Polat, Omer Aydin, Omer Faruk Karatas   +6 more
wiley   +1 more source

A phase 2 trial of gemcitabine plus toripalimab for cisplatin-ineligible patients with recurrent or metastatic nasopharyngeal carcinoma

Cell Reports Medicine
Summary: Cisplatin is a cornerstone chemotherapy for nasopharyngeal carcinoma (NPC); however, certain patients are ineligible for cisplatin-based regimens.
Xiong Zou, Xi Ding, Zheng-Kai Feng, Yan-Feng Ouyang, Hui-Feng Li, Kai Wen, Zhi-Qiang Wang, You-Ping Liu, Yong-Long Liu, Wei-Jing Zhang, Qi Yang, Si-Yuan Chen, Yu-Long Xie, Ruo-Qi Xie, Chao Lin, Chen-Mei Gu, Pei-Yu Huang, Rui Sun, Yi-Jun Hua, Rui You, Ming-Yuan Chen   +20 more
doaj   +1 more source

Variations in Treatment Prescription and Survival Outcomes Between Older and Younger Patients With Mucosal Head and Neck Squamous Cell Carcinoma Treated With Radiotherapy

Head &Neck, EarlyView.
ABSTRACT Purpose To investigate treatment variations and outcomes between older (≥ 70 years) and younger (< 70 years) patients with mucosal head and neck squamous cell carcinoma (mHNSCC) treated with radiotherapy. Methods A multicenter retrospective review of patients diagnosed from 2010 to 2018 was conducted.
Farhannah Aly, Joseph Descallar, Purnima Sundaresan, Alexis Andrew Miller, Lois Holloway, Shalini Vinod   +5 more
wiley   +1 more source

Incidence and Site‐Specific Risk Factors of Jaw Osteoradionecrosis for Head and Neck Patients in the IMRT/VMAT Era: Evidence From a Large, Hospital‐Based Cohort

Head &Neck, EarlyView.
ABSTRACT Purpose Osteoradionecrosis (ORN) of the jaw remains a serious late complication of head and neck cancer (HNC) radiotherapy. Although intensity‐modulated radiotherapy (IMRT) and volumetric‐modulated arc radiotherapy (VMAT) are expected to reduce ORN risk, large real‐world data in the modern era are limited.
Fang‐Yu Wu, Hui‐Hsin Ko, Hsiang‐Fong Kao, Shih‐Jung Cheng   +3 more
wiley   +1 more source

Infiltrating B-cell subtypes and associated hub genes in nasopharyngeal carcinoma identified from integrated single-cell, bulk RNA-sequencing, and immunohistochemical data

Hereditas
Background Nasopharyngeal carcinoma (NPC) is associated with lymphocyte infiltration; however, the majority of research on NPC has focused on the role of T cells, with relatively little known about the roles of B cells and their subtypes.
Fangyan Zhong, Junjun Chen, Tianzhu Lu, Lin Zhang, Zhiliang Liu, Chunhong Guan, Xiaopeng Xiong, Xiaochang Gong, Jingao Li   +8 more
doaj   +1 more source